CNBC · General

Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week

· By Elsa Ohlen
Story summary

Novartis is planning to buy U.S.-based biotech Excellergy for up to $2 billion, betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market, the Swiss pharmaceutical giant said Friday.

Read at CNBC

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.

Your local edition.

Choose a timezone for story timestamps and date filters.